Video Series

Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.

Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to prevent high-cost care episodes, emphasizing the need for predictive analytics, streamlined access, and real-world comparative data to guide treatment sequencing decisions.

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion (DM-BUP) was associated with lower total health care costs compared with other therapies, outlining strategies managed care organizations can use to promote cost-effective treatment adoption.

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial.

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through either upfront intensive approaches or thoughtful sequential doublet therapies.

Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ongoing treatment challenges.

Explore the critical role of biomarkers in diagnosing desmoid tumors and the importance of early detection for patient quality of life.

Panelists discuss how payer access challenges can determine whether patients receive therapy at all, with strategies including hospitalization for first cycles, advance prescription preparation, and recognition that oral regimens significantly impact quality of life for patients requiring lifelong treatment.

Panelists discuss how prescription digital therapeutics can expand access to specialized mental health interventions in underserved rural communities where traditional therapy resources are scarce or unavailable.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.

Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.

Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.

Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.

Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.

Panelists discuss how support networks and coordinated care are essential for delivering third-line metastatic colorectal cancer therapies effectively in the community.

Panelists discuss how addressing barriers and sharing real-world data can increase community confidence in prescribing third-line metastatic colorectal therapies.

Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.

Exploring the Heterogeneous Nature of Desmoid Tumors

Panelists discuss how managing oral therapy toxicities requires preemptive planning, multidisciplinary team involvement, patient and family education, and close monitoring for drug interactions and adherence issues, emphasizing the need for experienced centers with proper support infrastructure.

Panelists discuss how prescription digital therapeutics like Daylight show promise for treating depression and anxiety but face significant accessibility barriers due to lack of payer coverage and high out-of-pocket costs.

Key Background Information on Desmoid Tumors

Panelists discuss how implementing oral regimens faces significant operational barriers including formulary restrictions, prior authorization requirements, insurance coverage differences between inpatient and outpatient settings, and the need for careful monitoring protocols, especially during initial treatment cycles.